Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Caraway Therapeutics
Caraway Therapeutics to Present at 22nd Annual Needham Healthcare Conference
April 12, 2023
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics to Present at Stifel CNS Days
March 22, 2023
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
March 08, 2023
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics to Present at Two Upcoming Investor Conferences
October 07, 2022
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics to Present at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference
October 06, 2022
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics to Participate in William Blair Biotech Focus Conference
July 06, 2022
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics to Participate at Two Upcoming Investor Events
March 22, 2022
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics Receives Third Research Grant from The Michael J. Fox Foundation to Continue Advancement of TRPML1 Agonists for GBA-Parkinson’s Disease
January 26, 2022
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics to Present at Two Upcoming Investor Conferences
November 10, 2021
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 16, 2021
From
Caraway Therapeutics
Via
Business Wire
Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders
June 09, 2021
From
Caraway Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.